Teva Pharmaceutical Industries (NYSE:TEVA – Get Free Report) and ProQR Therapeutics (NASDAQ:PRQR – Get Free Report) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, earnings, analyst recommendations, profitability, institutional ownership and risk. Earnings & Valuation This table compares Teva […]
Critical Review: Athersys (NASDAQ:ATHX) versus Teva Pharmaceutical Industries (NYSE:TEVA) themarketsdaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from themarketsdaily.com Daily Mail and Mail on Sunday newspapers.
Kaya (OTCMKTS:KAYS – Get Free Report) and Teva Pharmaceutical Industries (NYSE:TEVA – Get Free Report) are both consumer discretionary companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, dividends, risk, institutional ownership, valuation, profitability and analyst recommendations. Insider and Institutional Ownership 49.7% of Teva […]
Kaya (OTCMKTS:KAYS – Get Free Report) and Teva Pharmaceutical Industries (NYSE:TEVA – Get Free Report) are both consumer discretionary companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, institutional ownership, risk, dividends, analyst recommendations, profitability and earnings. Earnings and Valuation This table compares Kaya […]
Highlights of the EMA’s human medicine committee meeting, April 2021
8
The Committee for Medicinal Products for Human Use (CHMP) recommended eight drugs for approval and nine indication extensions.
The European Medicines Agency (EMA) has recently announced the results of its April 2021 Committee for Medicinal Products for Human Use (CHMP) Meeting. In the meeting, the committee recommended eight new medicines for approval, including two orphan drugs, taking the total granted positive opinions this year to 34.
Recommended for approval
The committee granted its positive opinion to
Enspryng (satralizumab), an orphan drug for the treatment of neuromyelitis optica spectrum disorders (NMOSD) in patients from 12 years of age who are anti-aquaporin-4 IgG (AQP4-IgG) seropositive. See more details in the news announcement in the grid below. NMOSD is a rare and life-threatening condition affecting the optic nerves and spinal cord. The disorder, thought to be caused by the immune system